Business Wire

FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib

Financing extends Company’s cash runway beyond important clinical milestones anticipated beginning in 2H25, supporting the ongoing execution of the FORTE Master Protocol evaluating plixorafenib as a ...
Hosted on MSN

Fore Bio’s Plixorafenib Clears Interim Review in Brain Tumor Trial

PHILADELPHIA, PA — FORE Biotherapeutics announced that its investigational therapy plixorafenib has cleared an interim efficacy analysis in the Phase 2 FORTE basket study for patients with recurrent ...
Yahoo Finance

FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements

PHILADELPHIA, July 07, 2026--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced the closing ...
Business Wire

Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations

PHILADELPHIA--(BUSINESS WIRE)--Fore Biotherapeutics (Fore Bio), a precision oncology company dedicated to developing innovative treatments that provide a better outcome for cancer patients, today ...
Ventureburn

FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer Therapy

FORE Biotherapeutics Raises $67.4M to advance plixorafenib and support late-stage BRAF cancer therapy development worldwide.